Welcome to our dedicated page for McKesson SEC filings (Ticker: MCK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking opioid litigation accruals, thin distribution margins, and segment revenue shifts across McKesson’s 300-page annual report is no small task. Hidden in each 10-K or 8-K are critical clues about cash-flow timing, specialty drug pricing, and how the company’s vast pharmaceutical distribution network manages working capital. That complexity leaves many investors asking, “Where do I even start with McKesson SEC filings explained simply?�
Stock Titan solves that problem. Our platform pairs real-time EDGAR feeds with AI-powered summaries that translate technical disclosures into plain English. Whether you need the latest McKesson quarterly earnings report 10-Q filing, a McKesson 8-K material events explained alert on opioid settlements, or McKesson insider trading Form 4 transactions minutes after they post, we surface the facts and context automatically. You’ll see concise highlights of revenue by distribution segment, inventory turns, and litigation reserve movements—without digging through footnotes.
Use cases span every professional need: monitor McKesson executive stock transactions Form 4 before material announcements, compare gross-margin trends quarter over quarter, or dive into the McKesson proxy statement executive compensation to evaluate incentive alignment. Our coverage includes every form—from a McKesson annual report 10-K simplified to McKesson Form 4 insider transactions real-time—updated the moment they reach EDGAR. Understanding McKesson SEC documents with AI means investors, analysts, and compliance teams gain clear, immediate insights for confident decisions.
McKesson Corporation (NYSE: MCK) filed an 8-K summarizing the 30 July 2025 Annual Meeting results (Item 5.07).
- All 12 director nominees were re-elected; support exceeded 95% of votes cast, with only ~0.9-4.7 m "against" votes and 10.3 m broker non-votes per nominee.
- Shareholders ratified Deloitte & Touche LLP as independent auditor for FY 2026 by a 92% majority (102.2 m for / 8.6 m against / 0.1 m abstain).
- The advisory say-on-pay proposal also passed with ~92% approval (91.8 m for / 8.0 m against / 0.8 m abstain).
No additional business, strategic announcements or financial guidance were disclosed. The outcome signals continued investor confidence in board composition, executive pay and audit oversight but carries limited immediate valuation impact.
FAQ
What is the current stock price of McKesson (MCK)?
What is the market cap of McKesson (MCK)?
What is McKesson Corporation's core business?
How does McKesson support healthcare organizations?
What role does technology play in McKesson's operations?
In which markets does McKesson operate?
How is McKesson positioned in the competitive landscape?
What kinds of products does McKesson distribute?
How does McKesson ensure efficiency in its distribution network?
How does McKesson differentiate itself in the healthcare services industry?
